Skip to content

Study · Observational study · n = 22 · 2026

5 results

Effects of switching from somatropin to somapacitan on thyroid hormone levels in adult growth hormone deficiency: A pilot study.

Tsujimoto Y, Yamashiro K, Suzuki Y, Watanabe Y, Nishimura R

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society20 Jun 2026

PMID42335808 (opens in a new tab)DOI10.1016/j.ghir.2026.101720 (opens in a new tab)PepBankPUB-42335808
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with GH deficiency, IGF-1 did not change after switching from somatropin to somapacitan.

    In plain wordsIn adults with GH deficiency, IGF-1 did not change after switching from somatropin to somapacitan.

    Peptide
    Somapacitan
    Outcome
    No significant changeIGF-1
    Study

    n = 22

    Comparator
    Before switching from somatropin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-1 and TSH showed no changes; however, FT3 and FT4 levels significantly decreased, particularly in patients receiving levothyroxine.
    1 context sentence
    Summary · context
    We retrospectively studied 22 AGHD patients switched from somatropin to somapacitan at a university hospital (2017-2023).
  2. 02HumanObservational studyEfficacy outcome

    In adults with GH deficiency, TSH did not change after switching from somatropin to somapacitan.

    In plain wordsIn adults with GH deficiency, TSH did not change after switching from somatropin to somapacitan.

    Peptide
    Somapacitan
    Outcome
    No significant changeTSH
    Study

    n = 22

    Comparator
    Before switching from somatropin
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-1 and TSH showed no changes; however, FT3 and FT4 levels significantly decreased, particularly in patients receiving levothyroxine.
    1 context sentence
    Summary · context
    We retrospectively studied 22 AGHD patients switched from somatropin to somapacitan at a university hospital (2017-2023).
  3. 03HumanObservational studyEfficacy outcome

    In adults with GH deficiency, FT3 decreased significantly after switching to somapacitan, particularly among patients receiving levothyroxine.

    In plain wordsIn adults with GH deficiency, FT3 decreased after switching to somapacitan, particularly among those receiving levothyroxine.

    Peptide
    Somapacitan
    Outcome
    DecreaseFT3
    Study

    n = 22

    Comparator
    Before switching from somatropin
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-1 and TSH showed no changes; however, FT3 and FT4 levels significantly decreased, particularly in patients receiving levothyroxine.
    1 context sentence
    Summary · context
    We retrospectively studied 22 AGHD patients switched from somatropin to somapacitan at a university hospital (2017-2023).
  4. 04HumanObservational studyEfficacy outcome

    In adults with GH deficiency, FT4 decreased significantly after switching to somapacitan, particularly among patients receiving levothyroxine.

    In plain wordsIn adults with GH deficiency, FT4 decreased after switching to somapacitan, particularly among those receiving levothyroxine.

    Peptide
    Somapacitan
    Outcome
    DecreaseFT4
    Study

    n = 22

    Comparator
    Before switching from somatropin
    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-1 and TSH showed no changes; however, FT3 and FT4 levels significantly decreased, particularly in patients receiving levothyroxine.
    1 context sentence
    Summary · context
    We retrospectively studied 22 AGHD patients switched from somatropin to somapacitan at a university hospital (2017-2023).
  5. 05HumanObservational studyOther

    In adults switched to somapacitan, baseline FT4, rather than levothyroxine use, was independently associated with FT4 change.

    In plain wordsIn adults switched to somapacitan, baseline FT4 was independently linked to FT4 change, rather than levothyroxine use.

    Peptide
    Somapacitan
    Outcome
    Not applicableBaseline FT4 association with FT4 change
    Study

    n = 22

    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Multiple regression identified baseline FT4, rather than levothyroxine use, as independently associated with ΔFT4.
    1 context sentence
    Summary · context
    We retrospectively studied 22 AGHD patients switched from somatropin to somapacitan at a university hospital (2017-2023).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.